Grandori’s company SEngine, is preparing for a future in which cancer is not going to be treated according to cancer type – like breast or colon – but it will be treated based on its genetic underpinning. Read more: https://www.bizjournals.com/seattle/news/2019/02/16/fred-hutch-carla-grandori-cancer-treatment.html
Perspectives
Medgadget ft. Nu-Med Plus: Miniaturized Inhaled Nitric Oxide Delivery Units for Use in a Doctor’s Office
Nu-Med Plus, a medtech firm based in Utah, has developed a range of smart delivery devices for inhaled nitric oxide delivery, including a miniaturized unit that can operate in a doctor’s office. The innovation has been possible as parts of the drug patent for nitric oxide have been invalidated, meaning that the cost of the treatment […]
HOW TO LIVE TO 200 PODCAST features Dr. Ivan Liachko of Phase Genomics, ‘Cat Poop and the Secrets of the Microbiome’
Dr. Ivan Liachko, Founder & CEO of Phase Genomics, recently sat down with the How to Live to 200 Podcast to discuss his research including microbiomes, cat poop, genomics and key insights to help you live healthier and longer. Listen to the podcast here.
Study to explore viability of robot-built space outposts made from debris
There’s a lot of perfectly good space junk floating around up there, such as the upper stages of spent rockets. NanoRacks, a company dedicated to democratizing low-earth orbit by supporting innovations like cheap, easily deployed CubeSats, wants to use those in-space structures to build habitats known as Outposts. The Outposts could prove to be crucial […]
Seattle Angel Fund rebrands with launch of SeaChange, its largest raise to date
Angel investing is a tricky game. Supporting a startup just getting off the ground takes a lot of work. But after several years spent as a venture capitalist in the Bay Area, Susan Preston, now the managing member at Seattle’s SeaChange Fund, returned to the Pacific Northwest with an idea for how to spot sound […]
GeekWire: SEngine Receives 3.1m Grant to Bring Personalized Cancer Fighting Tech to Patients
Every patient’s cancer is unique and every patient responds to cancer drugs differently. But right now, all patients with the same kind of cancer are treated with the same drugs. SEngine Precision Medicine is hoping to change that with new platform, called PARIS, that grows and analyzes a patient’s cancer cells to figure out which drugs […]
s2s PR Representing Xconomy “What’s Hot in Seattle Biotech” Speakers
We’re proud to have cultivated the speaking engagement for Phase Genomics. CEO Ivan Liachko will present on the convergence of technology and the life sciences on June 12th in Seattle, alongside other biotech innovators such as Adaptive Biotechnologies and Silverback Therapeutics. Find the details and join us here: https://www.xconomy.com/whats-hot-in-seattle-biotech/speakers/
SEngine Discovery of Common Link in 28% of all Cancers Makes Medical, Life Science News
Scientists from Cure First and SEngine Precision Medicine discover common link in 28% of all cancers Read the story here
Testimonial: Opticyte
“s2s PR helped transform our complex medical messaging into a compelling and human story for both investors and potential partners. They helped increase the impact of presentations and branding to bring us closer to our business goals.” – Robert V. Masterson, CEO Opticyte, Inc
Seattle Business Magazine features SEngine Precision Medicine
SEngine Precision Medicine CEO Dr. Carla Grandori showcases SEngine’s scientific edge in functional precision oncology: